| Open Label Immunotherapy Trial for Ovarian Cancer (NCT03556566) | Immunitor LLC | 2018-07-01 |
| A Study of ZL-2306 (Niraparib) as Maintenance Treatment Following First-line Chemotherapy in Patients With Advanced Ovarian Cancer (NCT03709316) | Zai Lab (Shanghai) Co., Ltd. | 2018-06-30 |
| Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma (NCT03470805) | Grupo Español de Investigación en Cáncer de Ovario | 2018-06-21 |
| Use of New MolEcular MarkErs for a persoNalized Therapy in Ovarian Cancer-MEMENTO (NCT06917469) | Centro di Riferimento Oncologico - Aviano | 2018-06-20 |
| Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer (NCT03394885) | Duke University | 2018-06-19 |
| A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies (NCT03538028) | Incyte Biosciences International Sàrl | 2018-06-18 |
| Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients (NCT03278717) | University College, London | 2018-06-15 |
| 3D Prediction of Patient-Specific Response (NCT03561207) | KIYATEC | 2018-06-11 |
| Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer (NCT03539328) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 2018-06-01 |
| Clinical Study of Apatinib in the Treatment of Advanced Ovarian Cancer After the Failure of Standard Chemotherapy (NCT03547375) | Anhui Provincial Hospital | 2018-06-01 |
| Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy (NCT03558139) | Gilead Sciences | 2018-05-23 |
| Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors (NCT03490669) | AstraZeneca | 2018-05-21 |
| Lynparza Ovarian Cancer Clinical Experience Investigation (All Case Investigation) (NCT03505307) | AstraZeneca | 2018-05-21 |
| Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers (NCT03604653) | Holy Name Medical Center, Inc. | 2018-05-15 |
| Trial in Patients With Relapsed Ovarian Cancer (NCT03267589) | Nordic Society of Gynaecological Oncology - Clinical Trials Unit | 2018-05-14 |
| Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer (NCT07648745) | Prof Gordon Jayson | 2018-05-14 |
| Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer (NCT03519230) | BeiGene | 2018-05-14 |
| IMPACT: A Randomized WOO Study of Novel Therapeutic Agents in Women Triaged to Primary Surgery for EOC (NCT03378297) | Haukeland University Hospital | 2018-05-04 |
| BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas (NCT03355976) | Brown University | 2018-04-30 |
| CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers (NCT03454451) | Corvus Pharmaceuticals, Inc. | 2018-04-25 |
| A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer. (NCT03763123) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2018-04-24 |
| Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study (NCT03464201) | Grupo Español de Tumores Huérfanos e Infrecuentes | 2018-04-13 |
| Clinical Impact of Dedicated MR Staging of Ovarian Cancer (NCT03399344) | The Netherlands Cancer Institute | 2018-04-13 |
| Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer (NCT03300843) | National Cancer Institute (NCI) | 2018-04-11 |
| A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer (NCT03414047) | Eli Lilly and Company | 2018-04-10 |
| A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer (NCT03509636) | Jiangsu HengRui Medicine Co., Ltd. | 2018-04-04 |
| Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer (NCT03246074) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-04-03 |
| PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers. (NCT03283943) | British Columbia Cancer Agency | 2018-04-01 |
| Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube Cancer (NCT03410784) | National Cancer Institute, Naples | 2018-04-01 |
| FPA150 in Patients With Advanced Solid Tumors (NCT03514121) | Five Prime Therapeutics, Inc. | 2018-03-27 |
| Sentinel Lymph Node in Early Ovarian Cancer (NCT03452982) | Instituto de Investigacion Sanitaria La Fe | 2018-03-23 |
| Study to Assess Prevalence of BRCA1 and BRCA2 Mutation Among Ovarian, Primary Peritoneal and Fallopian Tube Cancer Patients in India (NCT03471572) | AstraZeneca | 2018-03-22 |
| Diaphragmatic Resection And Gynecological Ovarian Neoplasm (NCT03543462) | Catholic University of the Sacred Heart | 2018-03-20 |
| A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma (NCT03395080) | Leap Therapeutics, Inc. | 2018-03-05 |
| Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies (NCT03638206) | Shenzhen BinDeBio Ltd. | 2018-03-01 |
| Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer (NCT03225989) | Lokon Pharma AB | 2018-03-01 |
| IMX-110 in Patients With Advanced Solid Tumors (NCT03382340) | Immix Biopharma Australia Pty Ltd | 2018-02-15 |
| Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients (NCT03342417) | ExcellaBio LLC | 2018-02-14 |
| Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer (NCT03029403) | University Health Network, Toronto | 2018-02-12 |
| Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer (NCT04752865) | Hellenic Cooperative Oncology Group | 2018-02-09 |
| ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK (NCT03287271) | Michael McHale | 2018-02-06 |
| Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in Peritoneal Carcinomatosis From Ovarian Cancer (Cyto-chip 2) (NCT03931304) | Hospices Civils de Lyon | 2018-02-01 |
| QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer (NCT03164980) | North Eastern German Society of Gynaecological Oncology | 2018-02-01 |
| China Ovarian Cancer BRCA Testing Study (NCT03203993) | AstraZeneca | 2018-01-31 |
| OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer (NCT03180307) | On Target Laboratories, LLC | 2018-01-26 |
| Identification of Risk Factors and Construction of Prediction Model for Postoperative Intestinal Anastomotic Leakage in Ovarian Cancer (NCT06458361) | Zhongda Hospital | 2018-01-01 |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry (NCT03452774) | Massive Bio, Inc. | 2018-01-01 |
| Role of Surgery in Advanced Ovarian Cancer (NCT03980028) | Institut Claudius Regaud | 2018-01-01 |
| Shorter Scalp Cooling Time in Paclitaxel (NCT03266185) | Leiden University Medical Center | 2017-12-20 |
| The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer (NCT03551171) | Zai Lab (Shanghai) Co., Ltd. | 2017-12-19 |
| Phase Ib Study of Chiauranib in Patients With Ovarian Cancer (NCT03166891) | Chipscreen Biosciences, Ltd. | 2017-12-15 |
| Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients (NCT03321188) | Andrea Jewell | 2017-12-15 |
| Decision Support for BRCA Testing in Ethnically Diverse Women (NCT03470402) | Columbia University | 2017-12-13 |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies (NCT03329950) | Celldex Therapeutics | 2017-12-01 |
| QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy (NCT03197584) | ImmunityBio, Inc. | 2017-12-01 |
| Impact of Disney Movies During Chemotherapy on QOL of Gynecologic Oncology Patients (NCT03863912) | Medical University of Vienna | 2017-12-01 |
| Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer (NCT03858166) | Shandong University | 2017-12-01 |
| Assessment of the Minimal Residual Disease in Ovarian Cancer From Circulating Tumor DNA and Immune Repertoire (NCT03614689) | Geneplus-Beijing Co. Ltd. | 2017-11-25 |
| A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors (NCT03314935) | Incyte Corporation | 2017-11-21 |
| Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors. (NCT03345485) | Mundipharma Research Limited | 2017-11-08 |
| Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project (NCT03326713) | Rutgers, The State University of New Jersey | 2017-11-02 |
| Circulating Tumor DNA and BRCA Reversion Mutation in Advanced or Recurrent Ovarian Cancer Patients With Germline Mutation. (NCT05458973) | Yonsei University | 2017-10-31 |
| Comparative Effectiveness of HIPEC Following Interval Debulking Surgery in Patients With Advanced-stage Ovarian Cancer (NCT03448354) | Ajou University School of Medicine | 2017-10-26 |
| The Treatment Preferences of Women Diagnosed With Ovarian Cancer (NCT03367260) | Duke University | 2017-10-19 |
| Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer (NCT03249142) | ARCAGY/ GINECO GROUP | 2017-10-18 |
| VM110 in Detection of Microscopic Tumors: A Phase I Study (NCT03286062) | Fox Chase Cancer Center | 2017-10-12 |
| Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer (NCT03298074) | Yang Zhijun | 2017-10-01 |
| Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients (NCT03032614) | The University of Texas Health Science Center at San Antonio | 2017-09-30 |
| Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer (NCT03371693) | Zhongnan Hospital | 2017-09-30 |
| NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer (NCT03146663) | NuCana plc | 2017-09-28 |
| A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies (NCT02963831) | Ludwig Institute for Cancer Research | 2017-09-07 |
| Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors (NCT03170960) | Exelixis | 2017-09-05 |
| HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy (NCT03275194) | Instituto Nacional de Cancerologia de Mexico | 2017-09-02 |
| Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer (NCT03367182) | Yonsei University | 2017-09-01 |
| Unesbulin in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy (NCT03206645) | University of Oklahoma | 2017-08-28 |
| A Study of IMP4297 in Patients With Advanced Solid Tumors (NCT03508011) | Impact Therapeutics, Inc. | 2017-08-23 |
| A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms (NCT03219268) | MacroGenics | 2017-08-18 |
| Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies (NCT03323398) | ModernaTX, Inc. | 2017-08-15 |
| Liquid Biopsy Evaluation and Repository Development at Princess Margaret (NCT03702309) | University Health Network, Toronto | 2017-08-03 |
| Malignant Ascites in Ovarian Cancer: Impact of Total Paracentesis on Hemodynamics (NCT04032600) | Charite University, Berlin, Germany | 2017-08-01 |
| A Study of Apatinib Treatment in for Advanced Ovarian Cancer (NCT03393507) | The People's Hospital of Leshan | 2017-08-01 |
| Evaluation of the Sensitivity to Different Chemotherapy Regimens in Platinum-Partial Sensitive Recurrent Ovarian Cancer (NCT04337632) | Hunan Cancer Hospital | 2017-08-01 |
| Real-life Use of Niraparib in a Patient Access Program in Norway (NCT04785716) | Kristina Lindemann | 2017-07-31 |
| Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast (NCT03154281) | Avera McKennan Hospital & University Health Center | 2017-07-26 |
| Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer (NCT02978222) | Marker Therapeutics, Inc. | 2017-07-20 |
| EDMONd - Elemental Diet in Bowel Obstruction (NCT03150992) | Royal Surrey County Hospital NHS Foundation Trust | 2017-07-19 |
| Prevalence of BRCA1 and BRCA2 Mutations in Ovarian Cancer Patients in the Gulf Region (NCT03082976) | AstraZeneca | 2017-07-16 |
| Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer (NCT03188159) | National University Hospital, Singapore | 2017-07-01 |
| AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas (NCT03205176) | AstraZeneca | 2017-06-30 |
| QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer (NCT03127098) | NantCell, Inc. | 2017-06-26 |
| Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer (NCT03056833) | Ronald Buckanovich | 2017-06-10 |
| PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors (NCT03149549) | CytomX Therapeutics | 2017-06-01 |
| Hysterectomy and OPPortunistic SAlpingectomy (NCT03045965) | Göteborg University | 2017-06-01 |
| Evaluation of Surgical Excision of Cardiophrenic Lymph Nodes in Patients With Advanced Ovarian Cancer (NCT03235648) | Mansoura University | 2017-06-01 |
| A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers (NCT03073525) | Gradalis, Inc. | 2017-05-31 |
| Multi-maintenance Olaparib After Disease Recurrence in Participants With Platinum Sensitive BRCAm High Grade Serous Ovarian Cancer (NCT02855697) | The Christie NHS Foundation Trust | 2017-05-26 |
| An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies (NCT03144661) | Incyte Corporation | 2017-05-25 |
| Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors (NCT03189108) | National Cancer Institute (NCI) | 2017-05-22 |
| MAGE-A4ᶜ¹º³²T for Multi-Tumor (NCT03132922) | USWM CT, LLC | 2017-05-15 |
| A Study of SY-1365 in Adult Patients With Advanced Solid Tumors (NCT03134638) | Syros Pharmaceuticals | 2017-05-12 |